GERMANY - immatics receives EUR 40m
Biopharmaceutical company immatics biotechnologies GmbH has received EUR 40m in a second round of financing from a consortium of investors. This includes previous investors Wellington Partners and 3i, but also new investors National Technology Enterprises Company and Kfw and lead investor Dietmar Hopp. This is the largest private biotech financing round in Germany since 2001.
More on Early-stage
Karma et al. back €1.5m round for MeetFrank
Company will use the capital to launch its new "relocation without location" feature
Asabys leads €20m round for Anaconda Biomed
Previous backers Ysios Capital, Sabadell Venture Capital, Innogest and Omega Funds also take part
VC-backed ImCheck Therapeutics raises $53m series-B
Round is co-led by BPI France and Pfizer Ventures, the venture capital arm of pharmaceutical giant Pfizer
Blackstone backs $570m FerGene investment
Ferring is based in Saint-Prex, Switzerland, with 60 subsidiaries globally and 6,500 employees
Latest News
DBAG launches DBAG Fund VIII
Fund has raised €1bn of its €1.1bn target and plans to hold a final close in Q1 2020
Horizon invests in Ascent, bolts on TechHuddle
Horizon expects to merge the two IT services providers to create a business with 300 developers
Agilitas sells Recover Nordic to EQT
EQT deploys capital from its EQT VIII fund, which hit its €10.75bn hard-cap in 2018
Paine Schwartz invests in Warburton
Firm is investing from Paine Schwartz Food Chain Fund IV, which closed on $893m in 2014